VIV Stock Overview
Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Avivagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.005 |
| 52 Week High | CA$0.03 |
| 52 Week Low | CA$0.005 |
| Beta | 1.08 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -83.33% |
| 3 Year Change | -99.02% |
| 5 Year Change | -99.35% |
| Change since IPO | -99.76% |
Recent News & Updates
Shareholder Returns
| VIV | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -3.9% | 1.2% |
| 1Y | -83.3% | 53.0% | 6.1% |
Return vs Industry: VIV underperformed the Canadian Pharmaceuticals industry which returned 50.8% over the past year.
Return vs Market: VIV underperformed the Canadian Market which returned 3.9% over the past year.
Price Volatility
| VIV volatility | |
|---|---|
| VIV Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 13.8% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: VIV has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VIV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | G. F. Anthony | www.avivagen.com |
Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand.
Avivagen Inc. Fundamentals Summary
| VIV fundamental statistics | |
|---|---|
| Market cap | CA$388.47k |
| Earnings (TTM) | -CA$4.64m |
| Revenue (TTM) | CA$715.22k |
0.5x
P/S Ratio-0.1x
P/E RatioIs VIV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIV income statement (TTM) | |
|---|---|
| Revenue | CA$715.22k |
| Cost of Revenue | CA$409.83k |
| Gross Profit | CA$305.39k |
| Other Expenses | CA$4.95m |
| Earnings | -CA$4.64m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 42.70% |
| Net Profit Margin | -648.74% |
| Debt/Equity Ratio | -78.1% |
How did VIV perform over the long term?
See historical performance and comparison